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Abstract
Background: Laparoscopic cholecystectomy in acute calculous cholecystitis in high risk patients can lead to
significant morbidity and mortality. Percutaneous cholecystostomy may be an alternative treatment option but the
current literature does not provide the surgical community with evidence based advice.
Methods/Design: The CHOCOLATE trial is a randomised controlled, parallel-group, superiority multicenter trial.
High risk patients, defined as APACHE-II score 7-14, with acute calculous cholecystitis will be randomised to
laparoscopic cholecystectomy or percutaneous cholecystostomy. During a two year period 284 patients will be
enrolled from 30 high volume teaching hospitals. The primary endpoint is a composite endpoint of major
complications within three months following randomization and need for re-intervention and mortality during the
follow-up period of one year. Secondary endpoints include all other complications, duration of hospital admission,
difficulty of procedures and total costs.
Discussion: The CHOCOLATE trial is designed to provide the surgical community with an evidence based
guideline in the treatment of acute calculous cholecystitis in high risk patients.
Trial Registration: Netherlands Trial Register (NTR): NTR2666
Keywords: Acute cholecystitis, laparoscopic cholecystectomy, percutaneous cholecystostomy, percutaneous
drainage
Background
Acute calculous cholecystitis (ACC) is a frequently
encountered disease in the general surgical practice. In
young, otherwise healthy patients laparoscopic cholecys-
tectomy (LC) is the treatment of choice [1]. In elderly
patients with major comorbidity and seriously ill patients,
especially those already admitted to an intensive care unit,
percutaneous cholecystostomy (PC) seems preferable since
acute LC in these patients can result in serious morbidity
(up to 41% [2-7]) and mortality (up to 4.5% [2-6,8]). But
there is a remaining subgroup of patients who can be
defined as “high risk patients” based on their comorbidity
or disease severity but do not fit in either of the two afore-
mentioned categories.
B o t hL Ca n dP Ca r eo f t e nu s e di nt h i ss u b g r o u po f
patients but clear selection criteria for either treatment are
lacking and a number of questions regarding the safety
and efficacy of PC remain.
In the Dutch guidelines for the treatment of gallstone
disease [9] PC is indicated as a useful treatment option in
patients deemed unfit for surgery but it is left open to dis-
cussion whether routine use of PC has additional value
over antibiotic treatment in the therapy of ACC in the
general population. Little evidence is provided to support
this statement.
Most studies in the current literature addressing PC as
a therapeutic option in ACC in high risk patients are
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any medium, provided the original work is properly cited.retrospective with limited population sizes. Success rates
are fairly high, but mortality rates of PC (range 4-12.7%
[6]) are higher than those for LC. This could be attribu-
ted to selection bias as it is to be expected that those
patients treated with PC were in a worse clinical condi-
tion than those treated with LC.
A systematic review conducted in 2007 [6] analyzed the
safety and efficacy of PC in elderly and critically ill patients.
The review identified no clinical trials comparing PC with
LC and the included studies were mostly retrospective and
involved small patient populations. With a success rate of
91% in patients with confirmed ACC and a procedure
related mortality of 0.4% results of PC seemed promising.
The overall mortality was 12.7% and the overall complica-
tion rate was reported to be 6.2%. Complication rates were
not included in more than half of the studies thus leading
to an underestimation of the actual complication rate.
We performed a retrospective review of all patients
undergoing PC for acute calculous cholecystitis between
January 2009 and June 2010 [10]. A total of 27 patients
were included with a median age of 83 years. PC was per-
formed because of either comorbidity/age or duration of
symptoms. The success rate was 92.6% (N = 25) but the
complication rate was 22.2% (N = 6). The overall mortality
rate was 14.8% (n = 4) and the procedure related mortality
rate 3.7% (N = 1). With a mean follow-up of eight weeks
three patients developed recurrent cholecystitis and four
patients underwent an interval cholecystectomy.
Current literature and data from our own clinical
experience fail to answer the question which therapy is
the best option in ACC in high risk patients. At present
both treatment strategies are used in this patient category
and the preference and expertise of the responsible sur-
geon or the general opinion within the hospital usually
determines the choice of treatment.
The CHOCOLATE trial is designed to assess which
treatment modality is best suited for high risk patients
with ACC, with the aim to prove superiority of the laparo-
scopic cholecystectomy.
Methods
Design
The CHOCOLATE trial is a randomised controlled,
open, parallel, superiority multicenter study. Patients
will be randomly allocated to undergo either laparo-
scopic cholecystectomy or percutaneous drainage.
The aim of this study is to test the hypothesis that
laparoscopic cholecystectomy will lead to a reduction in
morbidity and mortality compared to percutaneous drai-
nage in high risk patients with acute calculous cholecystitis.
Primary & Secondary endpoints
The primary endpoint is a composite endpoint of all
major morbidity, re-intervention and mortality. Table 1
provides an overview of the definitions. Complications
occurring during the first 30 days subsequent to rando-
misation and need for reintervention and mortality dur-
ing the one year follow-up period will be compared.
The secondary endpoints include all individual com-
ponents of the primary endpoint and in addition all
minor complications including wound infection, bleed-
ing without need for transfusion or intervention and
urinary tract infection, difficulty of cholecystectomy (as
scored by VAS 1-10), total length of hospital stay, emer-
gency room visits for related medical problems, re-
admissions, duration of hospital and intensive care stay
and total (direct and indirect) costs.
Study Population
All patients presenting with ACC as defined according
tot the Tokyo Guidelines [12] to one of the participating
hospitals will be assessed for eligibility on presentation. If
patients meet the inclusion criteria they will be stratified
for hospital and randomised to undergo either LC or PC.
The in- and exclusion criteria are presented in table 2.
Randomisation
Patients will be randomly assigned to group A (laparo-
scopic cholecystectomy) or group B (percutaneous drai-
nage) as shown in the flowchart (Figure 1). Randomisation
is done by the study coordinator or primary investigator
using an online generator (ALEA 2.2, Academic Medical
Centre Amsterdam, the Netherlands https://nl.tenalea.net/
amc/ALEA/). Permuted-block randomisation with varying
block sizes with a maximum block size of four patients is
used to minimize the occurrence of chance imbalance and
preserve unpredictability. The sequence of the different
blocks is predetermined by an independent programmer
and concealed to all investigators. The blocks are gener-
ated separately within the different study sites, so stratifi-
cation according to hospital can be performed.
Treatment protocol
All patients presenting with suspected ACC in the
emergency department will undergo the standard
laboratory work-up and an arterial blood gas analysis.
An ultrasound of the abdomen will be performed to
confirm the diagnosis. If the findings on ultrasound
examination are inconclusive, a contrast enhanced CT-
scan of the abdomen will be performed.
When patients are eligible for inclusion and informed
consent is obtained randomisation will take place. The
allocated treatment has to be performed within 24
hours after randomisation. Figure 1 demonstrates the
study outline for included patients.
Group A: Laparoscopic cholecystectomy
LC will be performed by the four trocar technique
with transsection of the cystic duct and cystic artery
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the Dutch Guidelines for the treatment of gallstone dis-
ease [9]. LC will be performed by a surgeon trained and
experienced in laparoscopic surgery defined as > 100
laparoscopic procedures on a yearly basis.
Patients may receive prophylactic antibiotics according
to the local hospital protocol.
Antibiotic therapy will not be routinely continued
post-operatively unless the performing surgeon has
s t r o n gi n d i c a t i o n st od os o( such as (imminent) sepsis
or hemodynamic instability). In these cases the primary
investigator will be notified and the indications have to
be well documented.
Group B: Percutaneous drainage
PC will be performed by either ultrasound- or CT-
guided percutaneous drainage using an 8.5 French
maclock drain. Since there is no consensus in the cur-
rent literature [9,13] both the transhepatic and transper-
itoneal routes are allowed and which route is the safest
in the individual patient is to be judged by the perform-
ing radiologist.
Successful PC is defined as resolution of symptoms
and fever and normalization of C-Reactive protein and
white blood count. Failure to thrive, defined as clinical
deterioration, persisting fever, or increasing infection
parameters < 48 hours despite accurate drain position
and function will lead to LC.
Patients will be discharged with the drain in place.
The drain will be left in situ during a period of three
weeks, after which contrast-imaging of the drain will be
performed prior to removal to assess whether the drain
is still located in the gallbladder and whether there is a
patent cystic duct. Patients undergoing PC will not be
treated with antibiotics unless the patient is septic with
(imminent) hemodynamic instability.
When patients in either group develop an infectious
complication antibiotic therapy can be started. All
events will be recorded.
Data collection & follow-up
Each patient will receive an anonymous study number
w h i c hw i l lb eu s e df o rt h es t u d yc a s e - r e c o r d - f o r m s
(CRF) and the database.
On admission baseline patient characteristics includ-
ing, gender, age, body-mass-index (BMI), comorbidity,
previous abdominal surgery, APACHE-II score and
Table 1 Definitions of the primary endpoint.
Endpoint Definition
Complications
Intra-abdominal
abscess
Fever and/or elevated CRP/WBC and intra-abdominal fluid collection on CT-imaging or ultrasound.
Biliary injury All injuries of the intra- and extrahepatic biliary ducts including leakage of the biliary tree*.
Bleeding Drop in haemoglobin level requiring transfusion and/or reintervention.
Pneumonia Coughing or dyspnoea, radiography with infiltrative abnormalities, elevated infection parameters and positive sputum
culture.
Myocardial infarction Symptomatic elevated cardiac enzymes and abnormalities on electrocardiography or cardiac ultrasound.
Cerebrovascular (Temporary) loss of function of any body part or sense caused by cerebral ischemia or bleeding, proven on cerebral CT
imaging.
Thrombo-embolic Symptomatic deep venous thrombosis or pulmonary embolism, radiologically proven.
Need for re-intervention Relaparoscopy, laparotomy, ERCP, intervention radiology, readmission
Mortality
CRP - C-Reactive Protein; WBC - White Blood Cell count; CT - computed Tomography; ERCP - Endoscopic Retrograde Cholangiopancreaticography
* Type A: leakage of the minor hepatic ducts or cystic duct. Type B: leakage of common bile duct (CBD) without stricture - Type C: stricture of the CBD without
bile leakage - Type D: complete transection of the CBD with or without resection of a part of it [11].
Table 2 In- and exclusion criteria for eligibility for participation in the CHOCOLATE trial.
Inclusion Criteria Exclusion Criteria
- Age ≥ 18
- The diagnoses acute calculous cholecystitis defined according to the Tokyo Guidelines:
A. Local signs of inflammation: (1) Murphy’s sign, (2) Right upper quadrant mass/pain/
tenderness
B. Systemic signs of inflammation: (1) Fever, (2) elevated CRP, (3) elevated WBC count
C. Imaging findings: imaging findings characteristic of acute cholecystitis
Definite diagnosis:
(1) One item in A and one item in B are positive
(2) C confirms the diagnosis when acute cholecystitis is suspected clinically
- APACHE-II score ≥ 7 AND ≤ 14
- Written informed consent
- Onset of symptoms > 7 days before first
presentation
- Already admitted to ICU on presentation
- Pregnancy
- APACHE-II score ≤ 6O R≥ 15
- Acalculous cholecystitis
- Decompensated liver cirrhosis
- Mental illness prohibiting informed consent
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ting physician or the (local) study coordinator.
T h ed a t ar e g a r d i n gt h ep r o c e d u r ei n c l u d i n gd i f f i c u l t y ,
duration and complications, will be scored immediately
a f t e rt h ep r o c e d u r eb yt h ep e r f o r m i n gs u r g e o no r
radiologist.
During the admission a daily record of the patients
including vital signs, laboratory data and complications
will be kept.
After discharge the patient will be seen in the outpati-
ent clinic by a surgeon who will complete a question-
naire regarding the patient’s clinical condition. The
following 11 months the study coordinator will perform
t h ef o l l o wu pb yp h o n ea n df i l lo u tt h eC R Fr e g a r d i n g
complaints, readmissions and interventions.
All entered data will be checked for completion by the
study coordinator every three months and missing data
will be collected from the participating centers.
Figure 1 Flowchart of study outline of included patients.
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A data safety monitoring board (DSMB) consisting of
three independent members will monitor the safety and
efficacy of the trial.
There will be a meeting every six months in which the
DSMB will assess unblinded data and evaluate the cur-
rent status of the trial.
Adverse events
Adverse events are defined as any undesirable experi-
ence occurring to a subject during the study, whether or
not considered related to the intervention (i.e. LC or
PC).
All participating physicians will inform the study coor-
dinator of all (serious) adverse events ((S)AE) immedi-
ately on occurrence.
The primary investigator or study coordinator will list
all (S)AE and present these to the DSMB for every 30
randomized patients. All potential (S)AE will be reported
to the Central Committee on Research involving Human
Subjects ("Centrale Commissie Mensgebonden Onder-
zoek” [CCMO]) and the accredited medical ethical com-
mittee using the online module https://toetsingonline.
ccmo.nl.
Ethics
The CHOCOLATE trial is conducted in accordance with
the declaration of Helsinki and the Dutch “Wet Medisch
Wetenschappelijk Onderzoek met Mensen” (Medical
Research Involving Human Subjects Act).
The study protocol was approved by the “Verenigde
Commissies Mensgebonden Onderzoek” (United com-
mittees involving human research), the medical ethical
committee of the trial coordinating centre at the St
Antonius Hospital Nieuwegein on January 20
th 2011.
Secondary approval was obtained from all local ethics
committees in the participating centres.
Patients will give oral as well as written informed con-
sent prior to randomisation.
The CHOCOLATE trial is registered in the Dutch
Trial Register with identification number NTR2666.
Statistical aspects
Sample size calculation
The rates for the primary endpoint: major morbidity, re-
intervention and mortality for PC were 6.2, 13.1 and 12.7%
respectively in the review and 22.2, 18.5 and 14.8% in our
own series. We believe that the 6.2% complication rate in
the review is an underestimation of the actual rate, but
our own value of 22.2% was based on a retrospective,
selected group of patients to undergo PC mostly because
of their comorbidity. In these patients the complication
rate may very well be higher than in the intended popula-
tion of the CHOCOLATE trial. We therefore chose to
combine both complication rates and use the mean value
for our sample size calculation: 14.2%.
Morbidity rates for LC in high risk patients vary greatly
in current literature and are mainly based on small, retro-
spective populations. Mortality rates are described to be
around 4.5%. In our own series the complication rate was
13.6% and the mortality rate was 4.3%.
Our endpoint comprises major complications and mor-
tality. These rates cannot be simply added to each other
since mortality is in most case associated with major com-
plications. We therefore chose to add intervention rates
and complication rates and add up a hypothetical 1% for
mortality to ensure that no cases positive for the primary
endpoint were missed.
A decrease of the primary endpoint from 28.3% (PC
group) to 14.6% (LC group) with power 80%, alpha two-
sided 5%, Fisher exact, two proportions, 1:1 randomization
can be demonstrated by randomizing 2 × 140 patients (PS
Power and Sample Size Calculations, version 2.1.30, Febru-
ary 2003). With an expected loss to follow up of 1%, a total
of 284 patients will have to be included in the trial.
Descriptive statistics
Dichotomous data and counts will be presented in fre-
quencies. Continuous data will be presented in means
with a standard deviation or median value with a range.
Analyses
All patients will be analysed according to the intention to
treat approach. Baseline balance will be assessed based on
the following patient factors: APACHE-II score, sex, age,
duration of symptoms, previous abdominal surgery and
previous biliary history. A significant difference (p-value
< 0.05) in any of these factors between the two treatment
groups will be considered to be an imbalance, the most
important factors being APACHE-II score and age.
Although we do not expect this to occur, results within
the treatment groups will be stratified according to
APACHE-II score and age to assure reliable results.
For nominal data the Chi-Square test will be used. For
continuous data and counts the independent sample
t-test or one-way ANOVA will be used.
In the interim analysis (after one year) the occurrence
of the primary endpoint will be compared between the
two treatment groups. After the one year follow up of
the last patient is completed primary as well as second-
ary outcomes will be analyzed and compared.
Results will be presented as odds ratios with a corre-
sponding 95% confidence interval. A two-tailed P < 0.05
is considered statistically significant.
Premature termination of the study
The results of the interim analysis performed after the
first year of inclusion will be evaluated by the
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itored for benefit or harm using a restricted procedure
(Whitehead, 1997), designed according to the sample
size characteristics as described in the protocol. The
Peto approach will be followed meaning that the study
will only be stopped for beneficial effects in case of a
p-value < 0.001.
Safety monitoring will be performed specifically for
mortality with a two-sided type I error (a) of 0.05. A
relative risk of ≥ 2 will be considered reason to advise
to terminate the trial.
The trial will not be stopped for futility, the reason
being that this is the first randomized controlled trial on
this subject and treatment policy will be based on this
trial.
Feasibility
The CHOCOLATE trial was registered in the Dutch
Trial Register on December 27
th 2010. Approval from the
medical ethical committee was obtained on January 20
th
2011 and the first patient was randomised on February
23
rd 2011. Presently local approval by the ethical com-
mittees has been obtained in 15 participating centres and
six more centres have already been invited tot participate
in the study. After one year the inclusion rate will be
assessed. If Accrual is too slow, additional centres will be
invited to participate.
Discussion
The treatment of ACC in high risk patients is a much
debated subject in the surgical community and evidence
based guidelines are lacking. Current literature does not
provide an answer to the essential question which is the
better therapy: LC or PC? The CHOCOLATE trial is
designed with the aim to determine superiority of the
LC.
The best design for a therapeutic trial is a randomised
placebo-controlled, double-blind study but considering
the different interventions used in the CHOCOLATE
trial design is not feasible and therefore a randomised
open comparative design was chosen.
It is generally accepted that in young, otherwise healthy
patients LC is the treatment of choice for ACC [1]. In
elderly patients with major comorbidity or seriously ill
patients PC seems preferable. A subgroup of patients
remains which on the basis of co-morbidity or disease
severity can be defined as higher risk patients but cannot
be assigned to either of the mentioned categories. In this
subgroup of patients it remains unclear from which treat-
ment option they will benefit the most with the least risks.
The definition of this subgroup was set by a multicentre,
multidisciplinary expert panel. A number of imaginary
case scenarios including age, comorbidity, vital signs and
laboratory findings on presentation were presented to the
panel. Subsequently the panel was asked which therapy
(LC or PC) they would choose for their patient and
whether either one would be contra-indicated. Multiple
scoring systems were evaluated by the panel and the
APACHE-II score proved the best system to discriminate
between patient groups. There was consensus that patients
scoring < 7 should undergo emergency LC, and patients
scoring > 14 were to have PC. In patients scoring between
7 and 14, opinions differed and no consensus was reached
regarding which treatment was better, resulting in the
inclusion criterion of the APACHE-II score of 7-14.
We incorporated the condition that all LC patients
need to be operated on by or under supervision of a
laparoscopically experienced surgeon to ensure that all
patients receive the best possible treatment. A previous
study demonstrated significantly higher conversion rates
in LC for ACC when the surgery was performed by
non-laparoscopic surgeons [14]. Standardizing this
aspect of this treatment arm will make for a homoge-
nous patient group and prevent confounding based on
the performing surgeon.
With these medical, technical and ethical considera-
tions in mind we created the trial protocol according to
this described design.
Conclusion
The CHOCOLATE trial is a randomised controlled
multicenter study comparing laparoscopic cholecystect-
omy with percutaneous drainage to determine the best
treatment for acute calculous cholecystitis in high risk
patients.
Trial status
Approval of the study protocol from the central medical
ethical committee as well as all local ethics committees
has been obtained. Patients are being included in the
trial in all participating centres. Currently 34 patients
are enrolled in the CHOCOLATE trial.
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